Autopsy report · NCT02332889

Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Transition to a different immunotherapy strategy in the future at our institution”

The sponsor’s own words in the registry.

Life of this trial

Registered 6 months before it started.
Ran for about 1 year 3 months before it stopped.
1 participant enrolled.
Results were posted on the registry 1 year 9 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 1, Phase 2
Sponsor: University of Louisville
Sponsor type: University, hospital or other
Conditions: Gliomas; Medulloblastoma; Neuroectodermal Tumors, Primitive
Interventions: Vaccine (autologous dendritic cells); Decitabine and Hiltonol
Participants: 1
Sites: 3
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.